| Literature DB >> 32292524 |
Yanjun Liu1,2, Hongtao Liu2, Yi Li3,4, Rui Mao2, Huawu Yang1, Yuanchuan Zhang1, Yu Zhang2, Pengsen Guo2, Dafang Zhan1, Tongtong Zhang5,4.
Abstract
A growing body of evidence has suggested that circular RNAs (circRNAs) are crucial for the regulation of gene expression and their dysregulation is implicated in several diseases. However, the function of circRNAs in obesity remains largely unexplored.Entities:
Keywords: EZH2; adipogenesis; circSAMD4A; miR-138-5p; obesity
Mesh:
Substances:
Year: 2020 PMID: 32292524 PMCID: PMC7150479 DOI: 10.7150/thno.42417
Source DB: PubMed Journal: Theranostics ISSN: 1838-7640 Impact factor: 11.556
Figure 1Identification of differentially expressed circRNAs in obese patients. (A) Clustered heatmap of the differentially expressed circRNAs in VAT samples from 3 obese and 3 lean patients. Upregulated circRNAs are shown in red and downregulated circRNAs are shown in green. (B) Scatter plot showing differences in circRNA expression between the adipose tissues of obese patients and those of lean patients. The red dotted line indicated upregulation by 1.5-fold and the green line indicated downregulation by 1.5-fold. (C) Volcano plots comparing circRNA expression between obese and lean patients. The horizontal line corresponds to a P value of 0.05, and the vertical lines indicate upregulation and downregulation by 1.5-fold. The cyan and purple points indicate the differentially expressed circRNAs with a greater than 1.5-fold change between the two compared groups. (D) Numbers of identified circRNAs from different chromosomes. (E) Genomic origins of the differentially expressed circRNAs in the obese patients. (F) Differential expression of 15 circRNAs was validated in 20 adipose tissues from obese patients and 20 adipose tissues from lean patients using qRT-PCR. Data are presented as means ± SD; significant difference was identified with Student's t test. *P < 0.05; **P < 0.01; ns (not significant).
Figure 2Characterization of circSAMD4A in preadipocytes. (A) Genomic location of the hSAMD4A gene and of circSAMD4A. (B) Sanger sequencing showing the “head-to-tail” splicing of circSAMD4A in preadipocytes. (C) qRT-PCR of quantification of circSAMD4A and hSAMD4A mRNA expression in preadipocytes after treatment with RNase R. (D) qRT-PCR quantification of circSAMD4A and hSAMD4A mRNA expression in preadipocytes after treatment with Actinomycin D. (E) RNA FISH for circSAMD4A. Nuclei were stained with DAPI. Scale bar = 20µm. Data are presented as means ± SD; significant difference was identified with Student's t test. *P < 0.05; **P < 0.01; ns (not significant).
Figure 3CircSAMD4A as an independent risk factor that can predict non-remission in the obese patients. (A) CircSAMD4A expression in adipose tissues from 40 obese patients and 20 lean patients. (B) Pearson correlation between circSAMD4A expression and BMI in adipose tissues of 60 obese patients. (C) ROC curve for circSAMD4A indicating its diagnostic value in obese patients. (D) Schematic representation the siRNA sites specific to the back-splice junction of circSAMD4A. (E) Expression of circSAMD4A following siRNA treatment using qRT-PCR. (F-G) C/EBP-α and PPAR-γ expression was quantified using qRT-PCR after circSAMD4A knockdown during preadipocytes differentiation. (H) C/EBP-α and PPAR-γ expression was quantified using Western blot assay after circSAMD4A knockdown during preadipocyte differentiation. Data are presented as means ± SD; significant difference was identified with Student's t test. *P < 0.05; **P < 0.01; ns (not significant).
Figure 4CircSAMD4A acts as a miRNA sponge for miR-138-5p. (A) CircSAMD4A-miRNA-mRNA network and pathway analysis. (B) RIP experiments were performed using an antibody against AGO2 on extracts from preadipocytes. (C) CircRIP was performed using a circSAMD4A-specific probe and control probe in preadipocytes from obese patients. The enrichment of circSAMD4A and microRNAs was detected by qRT-PCR and normalized to the control probe. (D) Co-localization between circSAMD4A and miR-138-5p was observed by RNA in situ hybridization in preadipocytes. Nuclei were stained with DAPI. Scale bar = 20µm. (E) Schematic showing the predicted miR-138-5p sites in circSAMD4A. (F) Luciferase assays in preadipocytes co-transfected with a scrambled control, miR-138-5p mimic, and a luciferase reporter plasmid containing either wild-type circSAMD4A (circSAMD4A-WT). (G) qRT-PCR showing the level of circSAMD4A in the streptavidin-captured fractions from the preadipocytes lysates after transfection with biotinylated miR-138-5p or control RNA. CircANRIL (a circular RNA reported not to bind to AGO2) was used as a negative control. (H) Pearson correlation between circSAMD4A expression and miR-138-5p expression in adipose tissues of 60 obese patients using qRT-PCR. Data are presented as means ± SD; significant difference was identified with Student's t test. *P < 0.05; **P < 0.01.
Figure 5CircSAMD4A promotes adipogenesis via the miR-138-5p/EZH2 pathway. Quantification of EZH2 expression by qRT-PCR following (A) miR-138-5p knockdown or (B) circSAMD4A overexpression. Quantification of EZH2 expression by qRT-PCR following transfection with (C) circSAMD4A-specific siRNAs or (D) miR-138-5p mimic was quantified with qRT-PCR. Luciferase assay where preadipocytes were co-transfected with (E) scrambled control, circSAMD4A expression plasmid, and a luciferase reporter plasmid containing either wild-type EZH2 (EZH2-WT) or (F) EZH2 construct with mutated miR-138-5p binding sites (EZH2-mut). (G-H) Reversion assays using vectors overexpressing or konckdown circSAMD4A, as well as miR-138-5p mimics or inhibitors. Data are presented as means ± SD; significant difference was identified with Student's t test. *P < 0.05; **P < 0.01; ns (not significant).
Figure 6AAV9-mediated circSAMD4A downregulation counteracts HFD-induced obesity. (A) Administration of AAV9 vectors through tail vain injection of mice. (B) C57BL6 mice were fed HFD for 8 weeks and then administered with AAV-si-mmu_circ0000529 vectors (AAV-si-mmu_circ). Control mice received AAV-Scramble. Representative images of the HE staining of the VAT from mice administered with either AAV vectors. (C) Body weight in C57BL6 mice treated with AAV-si-mmu_circ or AAV-Scramble. (D) Representative images of the mice administered with AAV-si-mmu_circ or AAV-Scramble. (E) Glucose tolerance was determined after the intraperitoneal injection of glucose. (F) Insulin sensitivity was determined after an intraperitoneal injection of insulin. (G) Fat and lean mass of circRNA knockdown and control mice were determined. (H) Food intake, (I) O2 (J) CO2 production and (K) Heat generation consumption were measured during dark and light cycles in a 24-hour feeding period in metabolic chambers. Data are presented as means ± SD; significant difference was identified with Student's t test. *P < 0.05; **P < 0.01. Scale bar = 100µm.